BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
A pilot phase II study with brentuximab vedotin as pre-ASCT induction therapy in relapsed/refractory Hodgkin\'s lymphoma patients non-responding to IGEV salvage treatment.
Epistemonikos ID: e68e7539235dbf6eb8933eac650806d20de5efea
First added on: May 12, 2024